Indo Us Bio-Tech FY26 Financial and Governance Update

Revenue grew to Rs 110.44 crore; Profit After Tax declined to Rs 13.12 crore.

Reader Takeaway: Revenue grew despite profit pressure, but serious audit qualifications regarding record maintenance warrant investor caution.

What just happened

Indo Us Bio-Tech has released its financial results for the fiscal year ending March 31, 2026, alongside a series of leadership changes and audit disclosures. While top-line growth was achieved, the company faced a bottom-line contraction. The Board has decided against recommending a dividend for the year.

Why this matters

The company’s auditor report and secretarial audit contain significant qualifications. Specifically, the auditors could not verify details regarding trade receivables, payables, and cash sales. Furthermore, statutory registers—including those for share transfers and related party transactions—were reported as unavailable for verification, raising concerns about corporate governance and internal control transparency.

Board and Auditor Changes

M/s. Gautam N Associates resigned as Statutory Auditors on June 15, 2026, with M/s. Bhagat & Associates appointed to fill the vacancy. Additionally, Mrs. Neha Sachin Patel resigned as an Independent Director in April, with Mrs. Hemanshi Darsh Soni appointed as her successor.

Risks to watch

Investors should closely track the company's ability to rectify the lack of statutory documentation and historical digital database records. The inability of auditors to confirm balances for trade receivables, payables, and loans remains a primary area of concern for institutional and retail holders.

What to track next

The 22nd Annual General Meeting, scheduled for September 30, 2026, will serve as a key forum for shareholders to seek management clarification on the audit observations and the status of the company's internal record-keeping.